BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...commercial officer. He was VP of business development and strategic planning at Durect Corp. (NASDAQ:DRRX). WindMIL Therapeutics Inc....
...as CFO, effective March 30. He is EVP and CFO at Progenics Pharmaceuticals Inc. (NASDAQ:PGNX). WindMIL...
...lymphocytes and hit a broader range of antigens than peripheral blood-derived CAR Ts (see “ WindMIL...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

...as EVP and CSO of WindMIL Therapeutics Inc.; Borrello is a senior clinical adviser to the company. WindMIL’s...
...expanded over 7-10 days; the resulting MILs are infused back into the patient. Before launching WindMIL...
...Data are expected early this year from a Johns Hopkins-sponsored Phase II trial in MM. WindMIL...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...disease company, Mayer was EVP and CCO of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL). Cancer immunotherapy company WindMIL Therapeutics Inc....
BioCentury | Apr 26, 2019
Company News

Management tracks: Canbridge, Averum, WindMIL

...was acquired by molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN) last year. Cancer immunotherapy company WindMIL Therapeutics Inc....
BioCentury | Dec 20, 2018
Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

...clinical operations and translational sciences from VP. All are newly created positions. Cancer immunotherapy company WindMIL Therapeutics Inc....
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...two cell types with cancer cells and drive up cytotoxic cytokine production. An abstract from WindMIL Therapeutics Inc....
...more potent antigen-specific cytotoxic activity than peripheral blood-sourced T cells transduced with the same CAR. WindMIL...
...at Chapel Hill, Chapel Hill, N.C. University of Texas MD Anderson Cancer Center, Houston, Texas WindMIL Therapeutics Inc....
BioCentury | Jun 22, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...Camden Partners Nexus and the Kinneret Group participated alongside existing investors Domain Associates and FoxKiser. WindMIL...
...inception (see "WindMIL Reveals Cell Immunotherapy Technology" ). Qiming's Mark McDade and Anna French joined WindMIL's...
...Fund I, which it launched in April (see "Qiming's Cross-Border Connection" ). WindMIL Therapeutics Inc., Baltimore, Md. Sandi Wong WindMIL Therapeutics Inc....
BioCentury | Jun 18, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...Camden Partners Nexus and the Kinneret Group participated alongside existing investors Domain Associates and FoxKiser. WindMIL...
...President and CEO Brian Halak, who is also a partner at Domain, told BioCentury that WindMIL...
...inception (see "WindMIL Delivers Bone Marrow-Derived Lymphocytes" ). Qiming's Mark McDade and Anna French joined WindMIL's...
BioCentury | Oct 6, 2017
Company News

WindMIL reveals cell immunotherapy technology

...lymphocytes (MILs) in a Phase IIb trial alongside other therapies in patients with multiple myeloma. WindMIL...
...told BioCentury that while others are mostly developing cell therapies for immunotherapy using peripheral blood, WindMIL...
...La Jolla last week. WindMIL Therapeutics Inc. , Baltimore, Md. Business: Cancer, Gene/Cell therapy Mary Romeo The Johns Hopkins University WindMIL Therapeutics Inc....
BioCentury | Oct 5, 2017
Company News

WindMIL delivers bone marrow-derived lymphocytes

...lymphocytes (MILs) in a Phase IIb trial alongside other therapies in patients with multiple myeloma. WindMIL...
...told BioCentury that while others are mostly developing cell therapies for immunotherapy using peripheral blood, WindMIL...
...university completed a Phase I trial of the MILs and began the Phase II trial. WindMIL...
Items per page:
1 - 10 of 15
BioCentury | Mar 6, 2020
Management Tracks

Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more

...commercial officer. He was VP of business development and strategic planning at Durect Corp. (NASDAQ:DRRX). WindMIL Therapeutics Inc....
...as CFO, effective March 30. He is EVP and CFO at Progenics Pharmaceuticals Inc. (NASDAQ:PGNX). WindMIL...
...lymphocytes and hit a broader range of antigens than peripheral blood-derived CAR Ts (see “ WindMIL...
BioCentury | Feb 26, 2020
Emerging Company Profile

WindMIL: T cell source is key

...as EVP and CSO of WindMIL Therapeutics Inc.; Borrello is a senior clinical adviser to the company. WindMIL’s...
...expanded over 7-10 days; the resulting MILs are infused back into the patient. Before launching WindMIL...
...Data are expected early this year from a Johns Hopkins-sponsored Phase II trial in MM. WindMIL...
BioCentury | Jan 7, 2020
Company News

Management tracks: Rhythm, Mirati, Aura, IFM, a16z, Cambrex, Alzheon and more

...disease company, Mayer was EVP and CCO of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL). Cancer immunotherapy company WindMIL Therapeutics Inc....
BioCentury | Apr 26, 2019
Company News

Management tracks: Canbridge, Averum, WindMIL

...was acquired by molecular diagnostics company Myriad Genetics Inc. (NASDAQ:MYGN) last year. Cancer immunotherapy company WindMIL Therapeutics Inc....
BioCentury | Dec 20, 2018
Company News

Management tracks: Evox names Moses chairman; Kapeller joins GV

...clinical operations and translational sciences from VP. All are newly created positions. Cancer immunotherapy company WindMIL Therapeutics Inc....
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...two cell types with cancer cells and drive up cytotoxic cytokine production. An abstract from WindMIL Therapeutics Inc....
...more potent antigen-specific cytotoxic activity than peripheral blood-sourced T cells transduced with the same CAR. WindMIL...
...at Chapel Hill, Chapel Hill, N.C. University of Texas MD Anderson Cancer Center, Houston, Texas WindMIL Therapeutics Inc....
BioCentury | Jun 22, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...Camden Partners Nexus and the Kinneret Group participated alongside existing investors Domain Associates and FoxKiser. WindMIL...
...inception (see "WindMIL Reveals Cell Immunotherapy Technology" ). Qiming's Mark McDade and Anna French joined WindMIL's...
...Fund I, which it launched in April (see "Qiming's Cross-Border Connection" ). WindMIL Therapeutics Inc., Baltimore, Md. Sandi Wong WindMIL Therapeutics Inc....
BioCentury | Jun 18, 2018
Financial News

Qiming leads series B for cancer play WindMIL

...Camden Partners Nexus and the Kinneret Group participated alongside existing investors Domain Associates and FoxKiser. WindMIL...
...President and CEO Brian Halak, who is also a partner at Domain, told BioCentury that WindMIL...
...inception (see "WindMIL Delivers Bone Marrow-Derived Lymphocytes" ). Qiming's Mark McDade and Anna French joined WindMIL's...
BioCentury | Oct 6, 2017
Company News

WindMIL reveals cell immunotherapy technology

...lymphocytes (MILs) in a Phase IIb trial alongside other therapies in patients with multiple myeloma. WindMIL...
...told BioCentury that while others are mostly developing cell therapies for immunotherapy using peripheral blood, WindMIL...
...La Jolla last week. WindMIL Therapeutics Inc. , Baltimore, Md. Business: Cancer, Gene/Cell therapy Mary Romeo The Johns Hopkins University WindMIL Therapeutics Inc....
BioCentury | Oct 5, 2017
Company News

WindMIL delivers bone marrow-derived lymphocytes

...lymphocytes (MILs) in a Phase IIb trial alongside other therapies in patients with multiple myeloma. WindMIL...
...told BioCentury that while others are mostly developing cell therapies for immunotherapy using peripheral blood, WindMIL...
...university completed a Phase I trial of the MILs and began the Phase II trial. WindMIL...
Items per page:
1 - 10 of 15